The study DREAMM-9 evaluates belantamab mafodotin (belamaf) in combination with VRd for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplant (ASCT). It explores various dosing schedules and reports favorable safety profiles with notable ocular events. The study shows promising anti-myeloma responses across all cohorts, with higher belamaf doses correlating with increased rates of minimal residual disease negativity.

Key Points:

• Study (DREAMM-9) evaluates belamaf + VRd in newly diagnosed multiple myeloma (TI NDMM).
• Eight cohorts with different belamaf doses and schedules were studied.
• Safety: Majority experienced adverse events (AEs); ocular events and dose adjustments were common.
• Efficacy: High overall response rate (ORR) and complete response rate (CRR) observed across cohorts.
• Ocular Events: Managed with dose holds/reductions; longer dosing intervals reduced events.

Authors:
Saad Z. Usmani, MD; Michal Mielnik, MD; Mamta Garg, MD; Irwindeep Sandhu, MD; Al-Ola Abdallah, MD; Youngil Koh, MD, PhD; Albert Oriol, MD, PhD; Hang Quach, MD, FRACP, FRCPA, MBBS; Katja C. Weisel, MD; Aranzazu Alonso Alonso, MD; Enrique M Ocio, MD, PhD; Wojciech Janowski, MD; Chang-Ki Min; Karthik Ramasamy; Ricarda García Sánchez, MD; Paula Rodríguez-Otero, MD, PhD; Chris Brawley, MSc; Jacqueline L Egger, PhD; Morrys C Kaisermann, MD, PhD; Marek Hus, MD, PhD